# A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

> **NCT05906992** · PHASE3 · RECRUITING · sponsor: **Celltrion** · enrollment: 512 (estimated)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** CT-P53
- **BIOLOGICAL:** US-Ocrevus
- **BIOLOGICAL:** EU-Ocrevus

## Key facts

- **NCT ID:** NCT05906992
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-11
- **Primary completion:** 2027-02
- **Final completion:** 2029-01
- **Target enrollment:** 512 (ESTIMATED)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05906992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05906992, "A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05906992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*